Menu
Back to Journals » ClinicoEconomics and Outcomes Research » Volume 15
Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy [Corrigendum]
Authors Groessl EJ , Tally SR, Hillery N
Received 8 May 2023
Accepted for publication 8 May 2023
Published 15 May 2023 Volume 2023:15 Pages 331—332
Groessl EJ, Tally SR, Hillery N. Clinicoecon Outcomes Res. 2023;15:239—250.
Page 244, Results, first paragraph, the text “The main results of the Markov decision tree model are presented in Table 2. Over the course of the 5-year time horizon, the model estimated that 2.058 QALYs accumulated in the HHFT group while 1.996 QALYs accumulated in the standard LTOT group. The incremental difference of 0.062 QALYs is substantial given the 12% annual mortality rate in this cohort, and about half the cohort would be assumed to be deceased after 4 years. In addition to experiencing better health over time, the HHFT group also accrued lower total costs. Total costs from our 5-year model were $50,409 for the group receiving HHFT and $53,304 for those on standard LTOT therapy. This indicates that the costs associated with fewer moderate and severe exacerbations of COPD more than offset the device cost. A meaningful ICER cannot be calculated because the HHFT group was dominant, accruing better health at a lower cost”
should read
“The main results of the Markov decision tree model are presented in Table 2. Over the course of the 5-year time horizon, the model estimated that 2.047 QALYs accumulated in the HHFT group while 1.989 QALYs accumulated in the standard LTOT group. The incremental difference of 0.058 QALYs is substantial given the 12% annual mortality rate in this cohort, and about half the cohort would be assumed to be deceased after 4 years. In addition to experiencing better health over time, the HHFT group also accrued lower total costs. Total costs from our 5-year model were $47,516 for the group receiving HHFT and $51,455 for those on standard LTOT therapy. This indicates that the costs associated with fewer moderate and severe exacerbations of COPD more than offset the device cost. A meaningful ICER cannot be calculated because the HHFT group was dominant, accruing better health at a lower cost”.
The authors apologize for this error.
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.